{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Multiple Comparisons and Multiplicity: The hierarchical testing method will be used to maintain the', 'experiment-wise type I error of 5% level for the primary and key secondary analyses. The primary efficacy endpoint', 'will first be tested at the 5% type I error level. If the p-value of the primary analysis is 0.05, the secondary', 'hypotheses will be tested in the order listed for the secondary endpoints until either an analysis produces a', 'p-value >0.05 or all analyses result in a p-value 0.05.', 'Analysis of Pharmacokinetic Endpoint: Samples collected for pharmacokinetic analysis will be quantified for', 'a-HTBZ and B-HTBZ active metabolites and will be analyzed using population pharmacokinetic techniques.', 'Analysis methods will be detailed in a separate population pharmacokinetic analysis plan. Exploratory', 'pharmacokinetic/PD analysis may be performed on PD/safety endpoints.', 'Safety Analyses: All adverse events will be coded using the Medical Dictionary for Regulatory Activities. Each', 'patient will be counted only once in each preferred term or system organ class category for the analyses of safety.', 'Summaries will be presented for all adverse events, adverse events determined by the investigator to be related to', 'study treatment, serious adverse events, and adverse events causing withdrawal from the study. Summaries will be', 'presented by treatment group and for all patients. Patient listings of serious adverse events and adverse events', 'leading to withdrawal will be presented.', 'Observed values and changes from baseline in laboratory results and vital signs will be summarized descriptively.', 'Observed values in ECG parameters will be summarized, and counts and percentages of abnormal findings will be', 'presented. In addition, the number and percentage of patients with on-treatment QTcF values >450, >480, or', '>500 msec and change from baseline >30 or >60 msec will be presented.', 'The use of concomitant medications will be summarized by therapeutic class using descriptive statistics.', 'Concomitant medications will include all medications taken while the patient is treated with IMP.', 'Observed values in the C-SSRS and observed values and changes from baseline in the CDI-2 (Parent and Self-report', 'versions) will be presented by treatment group for all patients.', '20']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'TABLE OF CONTENTS', 'TITLE PAGE', '1', 'AMENDMENT HISTORY', '2', 'INVESTIGATOR AGREEMENT', '3', 'COORDINATING INVESTIGATOR AGREEMENT', '5', 'COORDINATING INVESTIGATOR AGREEMENT', '6', 'LABORATORY AND OTHER DEPARTMENTS AND INSTITUTIONS', '7', 'CLINICAL STUDY PERSONNEL CONTACT INFORMATION', '8', 'CLINICAL STUDY PROTOCOL SYNOPSIS', '10', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', '30', '1.', 'BACKGROUND INFORMATION', '33', '1.1.', 'Introduction', '33', '1.2.', 'Name and Description of IMP', '34', '1.3.', 'Findings from Nonclinical and Clinical Studies', '34', '1.3.1.', 'Nonclinical Studies', '34', '1.3.1.1.', 'Nonclinical Pharmacology', '34', '1.3.1.2.', 'Nonclinical Pharmacokinetics and Drug Metabolism', '35', '1.3.1.3.', 'Toxicology', '35', '1.3.2.', 'Clinical Studies', '36', '1.3.2.1.', 'Clinical Pharmacology Studies', '36', '1.3.2.2.', 'Clinical Safety and Efficacy Studies', '37', '1.3.2.3.', 'Pharmacometrics Analysis of TEV-50717 Active Metabolites to Support', 'Dose Selection and Pharmacokinetic Characterization in a Pediatric', 'Population', '37', '1.4.', 'Known and Potential Risks and Benefits to Human Patients', '38', '1.5.', 'Selection of Drugs and Dosages', '38', '1.5.1.', 'Justification for Dosage of Active Drug', '38', '1.5.2.', 'Justification for Use of Placebo', '38', '1.6.', 'Compliance Statement', '39', '1.7.', 'Study Population and Justification', '39', '1.8.', 'Location and Study Duration', '39', '2.', 'PURPOSE OF THE STUDY AND STUDY OBJECTIVES', '40', '2.1.', 'Purpose of the Study', '40', '21']\n\n###\n\n", "completion": "END"}